|Awarded On||March 29, 2012|
|Title||Development of a targeted therapy: a treatment that is able to suppress breast cancer initiating cells|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Mien-Chie Hung|
Tumor initiation cells (TICs, also known as cancer stems cells) are a small subpopulation of cells within the tumor that are highly aggressive and are suggested to be responsible for initiation of cancer and resistance to traditional cancer therapy. It has been reported that with conventional treatments, such as chemotherapy and radiotherapy, the percent of BTICs in the tumors increases from 9% to 74% after treatment, even though the overall tumor mass is reduced, making resistance to cancer treatment a major obstacle for breast cancer therapies. To our knowledge, there are no drugs that can effectively reduce breast tumor initiation cells (BTICs) in the clinic, although the EGFR/HER2 tyrosi...